Lake Street Capital Lowers Sensus Healthcare (NASDAQ:SRTS) Price Target to $13.00

Sensus Healthcare (NASDAQ:SRTS - Free Report) had its price objective reduced by Lake Street Capital from $18.00 to $13.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also weighed in on SRTS. HC Wainwright raised their target price on Sensus Healthcare from $11.00 to $12.00 and gave the company a "buy" rating in a report on Monday, February 10th. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, November 15th.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded down $0.11 during mid-day trading on Tuesday, reaching $4.47. The stock had a trading volume of 21,102 shares, compared to its average volume of 355,797. The stock has a market cap of $73.73 million, a P/E ratio of 11.18 and a beta of 1.28. The business's 50 day moving average is $6.13 and its 200 day moving average is $6.68. Sensus Healthcare has a fifty-two week low of $3.09 and a fifty-two week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its position in shares of Sensus Healthcare by 175.5% during the 4th quarter. Squarepoint Ops LLC now owns 85,677 shares of the company's stock worth $593,000 after purchasing an additional 54,576 shares during the last quarter. Man Group plc lifted its holdings in shares of Sensus Healthcare by 34.0% during the fourth quarter. Man Group plc now owns 59,338 shares of the company's stock worth $411,000 after buying an additional 15,059 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $381,000. Millennium Management LLC boosted its position in shares of Sensus Healthcare by 256.6% in the fourth quarter. Millennium Management LLC now owns 85,329 shares of the company's stock valued at $590,000 after acquiring an additional 61,403 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Sensus Healthcare in the fourth quarter worth $47,000. 25.30% of the stock is owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.